step with you,
every
of the way
Europe
with you, every step of the way
Teva Europe
Who are we?
For a start, we’re one of the world’s top 10 pharmaceutical companies*, with over 100 years’ experience. We develop and manufacture medicines and supplements for conditions ranging from the
common cold to symptoms associated with asthma. All in all, we possess an extremely broad portfolio of specialty, generic and over-the-counter medicines as well as APIs (active pharmaceutical ingredients). But, above all, we’re characterized by a relentless focus on patients. Everything we do — from producing pharmaceuticals to offering numerous other relevant services — is patient-driven. That’s how we intend to become the most indispensable medicines company for the world.
* Based on IMS data
6
7
We touch the lives of millions of people every day, and billions* every year. After all, everyone needs healthcare or medication at some point. We want to make sure that, when they do, their experiences are as pleasant and fulfilling as possible.
We’re in the people business Of course we facilitate this through our
by educating and helping people in a
ongoing innovation in pharmaceuticals.
number of different ways, including
In fact, patient centricity influences every-
through personal nurse services and
thing from our product design to treatment
psychological support.
initiation, monitoring and adherence. We also frequently interact with regulatory
E PR
-D
IA
O GN
SI
S A DI
GN
OS
IS C AC
EP
TA
E NC
PATIENT JOURNEY
A AD
PT
AT
N IO
authorities, healthcare providers, academia,
online patient support programmes for
pharmacies and other key players to make
those suffering from multiple sclerosis
sure that patients’ interests are always at the
and Parkinson’s disease**. Or, in this era of
forefront.
well-informed and empowered patients,
G IN T OM PER C BE EX AN
We talk here about the patient
TEVA PROVIDES: INFORMATION TEVA PROVIDES: SUPPORT
journey, but this also applies
TEVA PROVIDES: PERSONALIZED PROGRAMS
to healthy people who use our
TEVA PROVIDES: NURSING SERVICE
products because of lifestyle choices (e.g. contraception).
8
But we go much further, for example through
* Based on internal data ** Certain countries only
9
Our activities cover four main areas:
Our medicines are used by patients with conditions ranging from hay fever to cancer, and from headaches to heart disease.
Meeting an extraordinary range of needs
Generics Medicines whose patents have typically expired, but which we produce to the same high, exacting standards as the originals —
Specialty care medicines Proprietary brand-named medicines that have been developed to address unmet clinical needs.
11
usually at far lower prices. In 2013 we sold more than 1.3 billion tablets and capsules in Europe alone.*
We specialize in areas including central nerve system disorders, respiratory conditions, oncology, transplantation and pain. We help healthy people in their lifestyle choices, for example, through contraceptive pills or vitamin supplements. And we continue to develop new ways of addressing the unmet needs of
NTE
Over-the-counter
(new therapeutic entities)
patients worldwide. Everyday medicines, supplements, NTE is the name given to new delivery mechanisms, devices or
ointments and other products that are available without a prescription.
known molecules that we combine or use in a novel way to improve the quality of patients’ lives.
* Based on internal calculations
Each of these is explained in greater detail on the following pages >
10
To ensure we address the unmet needs of patients, we carry out a number of scientific collaborations with key institutes in the field of specialty medicines. These include:
Being special in specialty medicines
>T he National Network of Excellence in Neuroscience (NNE) A joint effort with Israeli academic and medical institutions to advance neuroscience research. > Collaborating on clinical development and dementia research with the UK National Health Service This initiative features a novel model created by the NOCRI (Office for Clinical Research Infrastructure) to streamline clinical development in the UK with a single point of entry into the UK health system.
Specific conditions and illnesses often require
We will invest approximately $20 million in clinical
more than just standard solutions. That’s
development in the UK and up to an additional
why we develop and manufacture specialty
$1 million for basic research into dementia.
medicines that make a real difference in people’s lives all over the world.
>R &D alliance for cancer DNA damage response drugs with Cancer Research Technology Ltd
We deliver innovative solutions for patients
We have signed a multi-project alliance agreement
and healthcare providers through our advanced
with Cancer Research Technology Ltd. (CRT),
medicines, devices and services.
Cancer Research UK’s technology development arm, to research and develop first-in-class cancer drugs
The six main specialty product areas
that modulate DNA damage and repair response
featured on the following pages are:
(DDR) processes in cancer cells.
> Central nervous system > Respiratory > Oncology care & pain > Women’s health
12
> E xamining multiple pathways of neuroprotection in Huntington’s disease We are participating in global scientific research to create a comprehensive understanding and drive
> Transplant
insights into neuroprotective therapeutic approaches
> Biologics & biosimilars
for Huntington’s disease (HD).
13
Central nervous system Respiratory Oncology care & pain Women’s health Transplant
Specialty care medicines Generics NTE (new therapeutic entities) Over-the-counter
Biologics & biosimilars
Realizing potential, every day Our central nervous system (CNS) medication is aimed at freeing
15
patients from disruptions to their daily lives, letting them be more than just their disease.
Central nervous system
of CNS products for the treatment of
but also on the side effects that could
We aim to help patients realise their potential,
multiple sclerosis (MS), sleep disorders and
potentially hold them back. We therefore
every day. An important factor in this is
the symptoms of Parkinson’s disease.
take the utmost care to ensure that the impact of our medication is focused
matching a drug to an individual’s needs;
14
in other words, determining the treatment
For many patients, maintaining a normal,
as much as possible on tackling the
regime that’s right for each specific situation.
active life is not only dependent on the
core problem.
To achieve this, we offer a strong portfolio
clinical efficacy of the medication they take,
Central nervous system
Laboratory of life
Respiratory Oncology care & pain Women’s health Transplant
Specialty care medicines Generics NTE (new therapeutic entities) Over-the-counter
Biologics & biosimilars
We’ve been present in the respiratory market for many years, producing much-needed medicines for millions of people. Our insightful ideas help patients play a more effective role in their own treatment.
17
Respiratory
optimally. Once that happens,
We want to improve lives by delivering
healthcare professionals can tackle
friendly, typically accessible solutions
respiratory conditions easier, without
in areas like asthma, COPD (chronic
having to change the medicines
obstructive pulmonary disease) and RSV
they prescribe.
(respiratory syncytial virus). We believe there is untapped potential in existing
We have a proven track record in
respiratory medicines, ready to be
respiratory care and are constantly
unlocked if we can only improve the
working on strengthening our portfolio.
way they are delivered to the lungs.
Our deep pipeline has 10 clinical-stage programmes; each represents a
After all, an effective combination of
considerable opportunity. In 2013 we
patient and inhaler is just as important
acquired MicroDose®, which further
as the combination of drugs inside the
complements our core programmes
device. Inhaler devices should therefore
in asthma and COPD. And we continue
be intuitive and straightforward;
to pursue the development of a
only then will patients feel completely
generic portfolio programme.
comfortable with them and use them
16
Just breathing should be easy
Central nervous system Respiratory Oncology care & pain Women’s health Transplant
Improving the lives of cancer patients
Specialty care medicines Generics NTE (new therapeutic entities) Over-the-counter
Biologics & biosimilars
Our oncology medicines are dedicated to improving the lives of people with cancer, through a portfolio of marketed products as well as continued investment in the development of novel oncology therapeutics.
Oncology care & pain
branded and generics oncology
Our diverse pipeline of small molecules
injectables, products to combat
and biologics holds great promise for
side-effects like neutropenia and
future therapies in hematologic malignancies,
treatment for breakthrough cancer pain,
solid tumours and supportive care.
which can be delivered by means of a
By combining our global heritage with
wearable patch to make it more
therapeutic innovation, we provide more
convenient for patients.
treatment choices for patients. We want to become the new innovative and
We want to build on these and other
ambitious oncology partner of choice.
products to become the most indispensable oncology partner of the future. In fact,
018 18
Many people around the world already
our long-term commitment to making
benefit from our very extensive portfolio
innovative and technologically advanced
of innovative, biosimiliar and generic
oncology medicines is a central pillar
molecules. For example, we already offer
of our overall strategy.
019 19
Central nervous system Respiratory Oncology care & pain Women’s health Transplant
Specialty care medicines Generics NTE (new therapeutic entities) Over-the-counter
Biologics & biosimilars
We develop and market many different products that are designed to improve women’s health and well-being throughout their lives.
Helping women all over the world
Women’s health Through listening to women all over the world and learning about their genuine needs and wishes, we develop products that provide them with the kind of care and help they’re looking for. Throughout the many different stages in their life. There are three main areas where this is evident. The first is in contraception, where through innovation, improved access and simplicity we are supporting this crucial life choice by offering many different ways of preventing pregnancy. The second is menopause; providing relief to many of the symptoms associated with what can be an extremely testing time in a woman’s life. Thirdly, we are currently exploring ways of improving fertility that are aimed at increasing the chances for many women who want to have children but are encountering difficulties. Further proof that we are channelling considerable resources into addressing women and their unique health needs — today and tomorrow.
20
21
Central nervous system Respiratory Oncology care & pain Women’s health Transplant
Specialty care medicines Generics NTE (new therapeutic entities) Over-the-counter
Biologics & biosimilars
An affinity for life
Harnessing the power of organisms 23
Our goal is to be the one stop shop for the transplant community, offering (branded) generic and innovative
Biologics & biosimilars
medicines to improve patient outcomes.
Biologics are medicines that are created by using living organisms, such as yeasts or proteins. In addition to developing our own
Transplant
biologics, we also offer many different kinds
Transplantation is a way is offering people
shop for transplantation medication in
We support the development of research
a new chance in life — and in some cases
the near future. Ultimately, we want the
aimed at progressing patient outcomes or
offering them a continuation of life itself.
transplant community to think of us
individualising therapies. And we encourage
This sub-category of biologics is derived
Our medication increases the chances of
every time, regardless of the product
initiatives to increase the number of organs
from living cells but is not identical to the
successful transplant outcomes.
or molecule required.
that are transplanted or transplantable.
original; hence the name. What you get is
We are currently building a portfolio of
As well as offering medicine, we also play a
with the same quality. In that sense,
products with the aim of being a one stop
part in progressing transplantation science.
biosimilars are to biologics what generics
of biosimilars.
the same effect — at a lower price but
are to branded drugs.
22
€
Specialty care medicines
> Generics
NTE (new therapeutic entities) Over-the-counter
Helping hundreds of millions* while saving billions through generics 2
Our generic medicines are of vital importance to
the European healthcare market. By manufacturing medicines whose patents have typically expired,
we drive down the cost because there is no need for
extensive — and expensive — research & development. We are the leading generics manufacturer in Europe1.
We produce over 1000 molecules, which form the basis
Our generic medicines are manufactured to exactly
the same demanding standards as the original
branded drugs. They also have the same effect on
the patient. The only significant difference is the price!
for tens of thousands* of different generic medicines.
Our estimates suggest that this leads to a reduction in the European healthcare budget by an average of €8 billion2
per year. This has two enormous benefits: it helps make healthcare more sustainable and affordable in general. And, because the investment costs are much lower for generics, this frees up money for us to invest in areas where breakthroughs are still required (see page 38).
1 Based on IMS data
2 Based on EGA & internal data
24
* Based on internal data
25
8 000 000 Specialty care medicines
> Generics
NTE (new therapeutic entities) Over-the-counter
We estimate that we save €8 billion every year from Europe’s healthcare budget through our cost-effective generic medicines* * Based on EGA & internal data
26
27
> Generics
Specialty care medicines > Branded/speciality Generics NTE (New Therapeutic Entities) < > NTE (new therapeutic entities) > Over The Counter Over-the-counter
New combinations mean renewed hope for patients 29 New therapeutic entities (NTEs) is the name given to known molecules that are combined, reformulated, delivered or used in a novel way. We are unique in that we have both generic and specialty molecules in-house, which we combine on an unprecedented scale. It is our ambition to start development of
This increases our scope for developing NTEs that can benefit patients in numerous ways: fewer pills are required for the same impact, reduced side-effects, more effective delivery and improved outcomes.
around 10 new NTE projects each year to 2020
28
We are currently exploring NTEs in many different areas that are of direct relevance to patients, including acute & chronic pain, schizophrenia, glaucoma and Crohn’s disease.
Specialty care medicines Generics NTE (new therapeutic entities) > Over-the-counter
Teaming up to empower people to care for themselves Millions of people throughout Europe use our over-the-counter products every day — ®
without even realizing it. That’s because we have teamed up with Procter & Gamble in a joint venture that combines our pharmaceutical expertise with its
branding and marketing skills.
31
The PGT Healthcare joint venture manufactures and markets more than 200 consumer healthcare brands in more than 70 countries around the world. Our portfolio includes Vicks — the world’s #1 selling cough & cold brand, ratiopharm — the #1 OTC brand in Germany, and other leading brands like Vibovit, Ambrobene, Hylak, Novo-Passit and Gastal. The OTC category is strategically important for both P&G and Teva. Our partnership with PMS 7690
PMS 367
PMS 298
PMS 431
P&G enables us to accelerate expansion into new countries and categories. Given global trends and demographics, we are confident that this is a valuable growth engine for Teva now and into the future.
48433_PGT_Mark with Pattern
randallh Friday, October 14, 2011 /PROJECT EDEN/+DESIGN/48384 PGT Brand Rollout/48684_Production/48384_PGT_Mark_101411
30
In addition to
our Teva brand, we offer
solutions to patients under a variety of other names. The Teva group is home to several other brands, including ratiopharm, PLIVA and Mepha.
Different names
32
same high quality
PLIVA
Mepha
ratiopharm
The largest pharmaceutical company in Croatia
Mepha is the leading supplier of generic
With its headquarters in the German town of Ulm, ratiopharm is the most widely used
and one of the largest in Southeast Europe,
medicines in Switzerland. It offers an extensive
and best known brand of drugs in Germany, recognized for decades as the epitome of
PLIVA can call on over 90 years of experience.
range of quality medication, which gives the
high quality at a reasonable price. With the ratiopharm brand Teva is leading in generics
Over 80% of the products manufactured by
desired therapeutic effect at a much lower
and over-the-counter products and also offers a number of biosimilars. The ratiopharm
PLIVA are exported.
price than the originals.
brand is also well known in Austria, Italy, Switzerland and Spain.
33
2 500 Teva packs are sold every
single minute of every single day in Europe, on average*
* Based on internal data
34
That’s an astonishing total of
1
3 5 9
8 0 0
packs sold in 2013 in Europe*
0 0 0
35
37
Proud of our heritage, inspired by new possibilities
36
We’ve come a long way since 1901, when three young pharmacists set up a small store in Jerusalem selling various kinds of medication. Today we employ close to 46,000 employees that are spread across 60 countries, following an approach best described as ‘local adaptation on a global scale’. Our growth has been both organic and through acquisition. Within the last two decades alone we have acquired more than 20 companies throughout the world, whose expertise and market knowledge add value to our existing capabilities. And we will continue to build on our strong foundations while seeking relevant new opportunities that benefit patients.
An ongoing commitment to innovation into R&D worldwide. In 2012 that meant that almost $1.5 billion channelled into developing breakthroughs, improving existing propositions and other activities designed to provide effective and affordable treatment for patients. We have a proven track record in innovation across our chosen areas of expertise, with a particularly strong emphasis on neurological disorders, respiratory ailments and oncology care. Our research activities for both generics and specialty pharmaceuticals are closely integrated to give synergy of integration. Work done on generics (especially on delivery technologies) can have equal utility in specialty medicines — and particularly for NTEs where formulators and analytics expertise in generics is key in the NTE development program. We also maintain strong partnerships with our academic and scientific partners. For example, the National Network for Excellence in Neuroscience, Cancer Research Technology and other pharmaceutical experts, healthcare providers and insurance companies to ensure that new developments are based on a broad range of relevant insights.
38
innovation
We reinvest approximately 7% of our revenue
39
Beyond pharmaceuticals 41
We’ve made our name by providing high-quality pharmaceuticals for decades. But that’s not all we do. In fact, we have a presence throughout the entire patient journey: from pre-diagnosis through diagnosis, from acceptance & adaptation to the stage at which people become experts in their conditions.
To give just one example, in the UK we offer support for those who have to inject their medicine on a daily basis, making their lives easier. We provide further information, personalized
programmes and nurse services when required. In fact, we have an entire European patient services department that is dedicated to understanding patient issues, and then exploring how we can
P
RE
DI
AG
NO
S SI D
G IA
NO
SI
S A
E CC
PT
AN
CE
PATIENT JOURNEY TEVA PROVIDES: INFORMATION TEVA PROVIDES: SUPPORT TEVA PROVIDES: PERSONALIZED PROGRAMS
40
TEVA PROVIDES: NURSING SERVICE
A
P DA
TA
TI
ON
NG MI RT CO PE BE EX AN
best address them.
As a business partner
As an employer
We continue to leverage the size and diversity of our
Headquartered in the Netherlands, Teva Europe employs
operations to bring the best quality pharmaceutical products
approximately 15,000 people. Being active in 36 countries,
to patient’s doorsteps.
including the 28 European Union member states, we are proud to say that our employees are the reason for our
Why choose Teva?
High standards of performance, efficiency and
sustained success. Their skills and dedication make us an
cost-effectiveness
industry leader. Their diverse perspectives, qualifications,
Through our extensive and efficient operational network
and talents are key to our ongoing accomplishments.
we can successfully maintain high standards of performance, efficiency and cost-effectiveness. Important elements in
Our company is a place where great ideas flourish.
this include a sound knowledge of pharmaceutical production
We believe in empowering our employees, presenting
technologies, in depth understanding of regulatory
them with new challenges and letting them grow and
requirements and quality management.
develop professionally.
Strict, regulated manufacturing
We provide our people with:
The manufacture of both generic and innovative drugs is
> A wide variety of jobs and fields of expertise
regulated strictly and follows the relevant cGMP (current
> A unique creative organizational culture
good manufacturing practices) standards, both in the lab and
> A wealth of opportunities for personal growth
43
at production sites. Our European FDA certified plants have been inspected over 200 times without incident.
Our employees enjoy prospects for genuine personal, professional and organizational development.
Patient safety is at the heart of our agenda and is one of our core principles. All of our medicines undergo thorough safety monitoring and evaluation processes at every stage of their lifecycle. We are committed to absolute transparency in exposing the benefits and risks of our medicines, and work in complete accordance with health authorities around the world.
42
Trusted brands: Teva, ratiopharm, PLIVA, Mepha
Quality medicines in generics, NTE, specialty and OTC
Over 15,000 dedicated employees in the EU**
On average, 2500 Teva packs are dispensed in the EU, every single minute of every single day**
No. 1 in generics*
The world of
We have a heritage stretching back over 100 years We are a global top 10 pharmaceutical company*
17 operating sites in the EU
Over 1000 molecules
45
A presence in 36 EU countries**
Teva saves an estimated €8 billion a year on the European healthcare budget*** Teva Europe dispenses 1.3 billion packs per year**
44
Europe
We do business with approx. 30,000 suppliers** * Based on IMS data ** Based on internal data *** Based on internal and IMS data
Over 60 sites across Europe: > Operations > R&D > Commercial
Teva Pharmaceuticals Europe Piet Heinkade 107 1019 GM Amsterdam The Netherlands P.O. Box 16416 1001 RM Amsterdam The Netherlands Tel: +31 (0)20 2193 200
[email protected] www.tevapharm.com
HQ/TV/14/0003
Europe
